Glycine Treatment of Prodromal Symptoms
Sponsor
Yale University (Other)
Overall Status
Completed
CT.gov ID
NCT00268749
Collaborator
Stanley Medical Research Institute (Other)
10
1
28.1
Study Details
Study Description
Brief Summary
This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Glycine Treatment of Prodromal Symptoms
Study Start Date
:
Jul 1, 2002
Actual Primary Completion Date
:
Nov 1, 2004
Actual Study Completion Date
:
Nov 1, 2004
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 1
|
Drug: glycine
0.8 g/kg/day
|
Outcome Measures
Primary Outcome Measures
- Scale Of Prodromal Symptoms total score [8 weeks]
Eligibility Criteria
Criteria
Ages Eligible for Study:
14 Years
to 35 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
age 14-35
-
meets SIPS criteria for psychosis prodrome
Exclusion Criteria:
-
current antipsychotic medication
-
more than 4 weeks of antipsychotic medication lifetime
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Yale University
- Stanley Medical Research Institute
Investigators
- Principal Investigator: Scott W Woods, MD, Yale University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT00268749
Other Study ID Numbers:
- 02T-175
First Posted:
Dec 22, 2005
Last Update Posted:
Mar 29, 2012
Last Verified:
Mar 1, 2012